Oppenheimer Lowers Evolent Health Price Target to $6
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 8 hours ago
0mins
Should l Buy EVH?
Oppenheimer lowered the firm's price target on Evolent Health to $6 from $12 and keeps an Outperform rating on the shares following the company's Q4 earnings release and newly issued guidance. The firm is lowering FY2026/2027 EPS estimates and issuing an initial FY2028 EPS estimate. Overall, Oppenheimer believes the more conservative posture toward reserves and the upside to margins from the significant new business, sets the company up for outsized growth in the coming years.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EVH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EVH
Wall Street analysts forecast EVH stock price to rise
14 Analyst Rating
13 Buy
1 Hold
0 Sell
Strong Buy
Current: 3.250
Low
5.00
Averages
9.33
High
16.00
Current: 3.250
Low
5.00
Averages
9.33
High
16.00
About EVH
Evolent Health, Inc. is a health care company connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses. The Company offers primary solutions, including specialty care management services and administrative services. It provides comprehensive quality management for oncology and cardiology patients from diagnosis through advanced care planning services, as well as identifying quality, lowest cost of care for outpatient orthopedic surgeries. Its administrative services solution includes an integrated value-based care platform designed to help customers manage and administer patient health in a cost-effective manner.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
EVOLENT HEALTH: OPPENHEIMER LOWERS PRICE TARGET FROM $12 TO $6
- Stock Price Adjustment: Evolent Health has reduced its target price from $12 to $6.
- Market Impact: This significant cut in target price may reflect changes in market conditions or company performance.
See More
Evolent Health to Participate in Investor Conferences
- Executive Participation: Evolent Health's executive management team will participate in upcoming investor conferences, aiming to enhance the company's transparency and trust in the capital markets through direct interaction with investors.
- Webcast Availability: The events will feature live audio webcasts and replays, allowing investors to access relevant information via Evolent's investor relations website, ensuring timely communication and broad outreach.
- Company Mission: Evolent specializes in achieving better health outcomes for individuals with complex conditions through solutions that simplify and reduce healthcare costs, thereby enhancing its competitive position in the healthcare industry.
- Industry Recognition: Evolent is consistently recognized as one of the top places to work in healthcare nationally, demonstrating its success in attracting and retaining talent, which further solidifies its leadership in the healthcare services sector.
See More
Evolent Health Q4 2025 Earnings Call Insights
- Revenue and EBITDA Performance: Evolent Health reported Q4 2025 revenue of $469 million and adjusted EBITDA of $37.8 million, both exceeding the midpoint of guidance, indicating sustained momentum in organic growth and profitability.
- Future Growth Expectations: CEO Seth Blackley forecasts approximately 30% revenue growth in 2026, with 65% of revenue expected to come from oncology, up from 36% in 2025, highlighting a strategic shift towards high-growth areas.
- Customer and Contract Expansion: The company migrated approximately 90% of Performance Suite revenue under a new model, retaining all key customers and signing two major new clients in the past year, enhancing market competitiveness and customer base.
- Financial Outlook and Challenges: Despite anticipating a $40 million headwind from exchange membership declines, the company plans to achieve $2.5 billion in revenue and $125 million in adjusted EBITDA, demonstrating confidence in future growth.
See More
KeyBanc Downgrades Evolent Health Rating Amid EBITDA Concerns
- Rating Downgrade: KeyBanc Capital Markets downgraded Evolent Health from overweight to sector weight due to concerns over the company's future EBITDA performance, reflecting a cautious market sentiment regarding its profitability.
- Earnings Beat: Despite the Q4 financial results released on the same day exceeding market expectations, analyst Matthew Gillmor noted that EBITDA is expected to be heavily weighted in H2 at 70%, indicating seasonal volatility in the company's earnings.
- Future Outlook: Gillmor also mentioned that the Street EBITDA target for 2027 is expected to be lowered to $187 million, suggesting a decline in market confidence regarding the company's long-term profitability.
- Strong Demand: Despite the downgrade, Evolent's late-stage pipeline remains robust, and high renewal rates with existing customers reflect strong demand among health plans to control specialty costs, particularly in oncology, supporting the company's shift to the PS 2.0 model.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perceptions of these firms.
- Market Reaction Insight: While specific rating changes are not detailed, analysts' opinions typically influence investor decisions, potentially leading to stock price fluctuations.
- Investor Focus: For those considering buying FSLR stock, analysts' insights will serve as a crucial reference point, likely impacting their investment strategies.
- Rating Change Transparency: Comprehensive information on analyst rating changes can be found on Benzinga's analyst ratings page, providing deeper market insights to assist investors in making informed decisions.
See More
Evolent Health Q4 Earnings Analysis and Outlook
- EBITDA Guidance Downgrade: Evolent Health's forecast for 2026 EBITDA is set between $110 million and $140 million, falling short of the $151.2 million reported for FY2025, indicating challenges in profitability recovery that may impact investor confidence.
- Q4 Revenue Performance: Evolent's Q4 revenue decreased by 27% to $468.7 million, yet it surpassed Wall Street's expectations of $467.5 million, demonstrating the company's ability to maintain market competitiveness amid adversity.
- Rising Debt Leverage: KeyBanc projects Evolent's debt leverage to rise to approximately seven times, reflecting financial management pressures that could lead to increased future financing costs and affect overall financial health.
- Retail Sentiment Shift: Despite a more than 5% drop in pre-market trading, retail investor sentiment on Stocktwits shifted from 'bearish' to 'neutral', indicating a reassessment of the company's future potential in the market.
See More
EVOLENT HEALTH: OPPENHEIMER LOWERS PRICE TARGET FROM $12 TO $6
- Stock Price Adjustment: Evolent Health has reduced its target price from $12 to $6.
- Market Impact: This significant cut in target price may reflect changes in market conditions or company performance.
See More
Evolent Health to Participate in Investor Conferences
- Executive Participation: Evolent Health's executive management team will participate in upcoming investor conferences, aiming to enhance the company's transparency and trust in the capital markets through direct interaction with investors.
- Webcast Availability: The events will feature live audio webcasts and replays, allowing investors to access relevant information via Evolent's investor relations website, ensuring timely communication and broad outreach.
- Company Mission: Evolent specializes in achieving better health outcomes for individuals with complex conditions through solutions that simplify and reduce healthcare costs, thereby enhancing its competitive position in the healthcare industry.
- Industry Recognition: Evolent is consistently recognized as one of the top places to work in healthcare nationally, demonstrating its success in attracting and retaining talent, which further solidifies its leadership in the healthcare services sector.
See More
Evolent Health Q4 2025 Earnings Call Insights
- Revenue and EBITDA Performance: Evolent Health reported Q4 2025 revenue of $469 million and adjusted EBITDA of $37.8 million, both exceeding the midpoint of guidance, indicating sustained momentum in organic growth and profitability.
- Future Growth Expectations: CEO Seth Blackley forecasts approximately 30% revenue growth in 2026, with 65% of revenue expected to come from oncology, up from 36% in 2025, highlighting a strategic shift towards high-growth areas.
- Customer and Contract Expansion: The company migrated approximately 90% of Performance Suite revenue under a new model, retaining all key customers and signing two major new clients in the past year, enhancing market competitiveness and customer base.
- Financial Outlook and Challenges: Despite anticipating a $40 million headwind from exchange membership declines, the company plans to achieve $2.5 billion in revenue and $125 million in adjusted EBITDA, demonstrating confidence in future growth.
See More
KeyBanc Downgrades Evolent Health Rating Amid EBITDA Concerns
- Rating Downgrade: KeyBanc Capital Markets downgraded Evolent Health from overweight to sector weight due to concerns over the company's future EBITDA performance, reflecting a cautious market sentiment regarding its profitability.
- Earnings Beat: Despite the Q4 financial results released on the same day exceeding market expectations, analyst Matthew Gillmor noted that EBITDA is expected to be heavily weighted in H2 at 70%, indicating seasonal volatility in the company's earnings.
- Future Outlook: Gillmor also mentioned that the Street EBITDA target for 2027 is expected to be lowered to $187 million, suggesting a decline in market confidence regarding the company's long-term profitability.
- Strong Demand: Despite the downgrade, Evolent's late-stage pipeline remains robust, and high renewal rates with existing customers reflect strong demand among health plans to control specialty costs, particularly in oncology, supporting the company's shift to the PS 2.0 model.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perceptions of these firms.
- Market Reaction Insight: While specific rating changes are not detailed, analysts' opinions typically influence investor decisions, potentially leading to stock price fluctuations.
- Investor Focus: For those considering buying FSLR stock, analysts' insights will serve as a crucial reference point, likely impacting their investment strategies.
- Rating Change Transparency: Comprehensive information on analyst rating changes can be found on Benzinga's analyst ratings page, providing deeper market insights to assist investors in making informed decisions.
See More
Evolent Health Q4 Earnings Analysis and Outlook
- EBITDA Guidance Downgrade: Evolent Health's forecast for 2026 EBITDA is set between $110 million and $140 million, falling short of the $151.2 million reported for FY2025, indicating challenges in profitability recovery that may impact investor confidence.
- Q4 Revenue Performance: Evolent's Q4 revenue decreased by 27% to $468.7 million, yet it surpassed Wall Street's expectations of $467.5 million, demonstrating the company's ability to maintain market competitiveness amid adversity.
- Rising Debt Leverage: KeyBanc projects Evolent's debt leverage to rise to approximately seven times, reflecting financial management pressures that could lead to increased future financing costs and affect overall financial health.
- Retail Sentiment Shift: Despite a more than 5% drop in pre-market trading, retail investor sentiment on Stocktwits shifted from 'bearish' to 'neutral', indicating a reassessment of the company's future potential in the market.
See More
